Ethicon purchase failure triggers Focal termination
This article was originally published in Clinica
Executive Summary
Focal has exercised its right to terminate its distribution agreement with Johnson & Johnson subsidiary Ethicon in regard to Focal's proprietary surgical sealant. Focal said that Ethicon failed to meet the agreed minimum purchases and, under the terms of the contract, Focal gave Ethicon 90 days notice from this month.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.